Suk-Hyung Kwon
Chief Executive Officer bei NOVAREX CO.,LTD.
Vermögen: 24 Mio $ am 31.03.2024
Profil
Suk-Hyung Kwon is currently the Chairman & Chief Executive Officer at NOVAREX Co., Ltd.
since 2019.
He is also the Chief Executive Officer at NOVAKMED since 2017 and the Chairman of the Korea Health Supplements Association since 2016.
Additionally, Dr. Kwon is a Senior Associate at STIC Investments, Inc. (South Korea).
Previously, he worked as a Director at Rexahn Pharmaceuticals, Inc. from 2001 to 2005.
Dr. Kwon holds a doctorate degree from Chung-Ang University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NOVAREX CO., LTD.
17,83% | 15.11.2023 | 3 344 214 ( 17,83% ) | 24 Mio $ | 31.03.2024 |
Aktive Positionen von Suk-Hyung Kwon
| Unternehmen | Position | Beginn |
|---|---|---|
| NOVAREX CO.,LTD. | Chief Executive Officer | 22.03.2019 |
| NOVAKMED | Chief Executive Officer | 02.01.2017 |
| Korea Health Supplements Association | Chairman | 25.02.2016 |
STIC Investments, Inc. (South Korea)
 STIC Investments, Inc. (South Korea) Investment ManagersFinance STIC Investments, Inc. (South Korea) is a private equity subsidiary of STIC Investments, Inc. founded in 1999 by Yong-Hwan Do and Byung-Won Choi. STIC Investments, Inc. (South Korea) is headquartered in Seoul, South Korea. | Private Equity Analyst | - |
Ehemalige bekannte Positionen von Suk-Hyung Kwon
| Unternehmen | Position | Ende |
|---|---|---|
| REXAHN PHARMACEUTICALS, INC. | Director/Board Member | 14.06.2005 |
Ausbildung von Suk-Hyung Kwon
| Chung-Ang University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
STIC Investments, Inc. (South Korea)
STIC Investments, Inc. (South Korea) Investment ManagersFinance STIC Investments, Inc. (South Korea) is a private equity subsidiary of STIC Investments, Inc. founded in 1999 by Yong-Hwan Do and Byung-Won Choi. STIC Investments, Inc. (South Korea) is headquartered in Seoul, South Korea. | Finance |
| NOVAREX Co., Ltd. | |
| Korea Health Supplements Association | |
| NOVAKMED |
